Stock Watch: Biosimilar Trends Percolate Through Roche’s Q3
Roche Expects Vabysmo’s Growth To Be Untroubled By Biosimilars
Pharmaceutical company managers may view biosimilar erosion of their products’ sales in the same rose-tinted light cast by Humira’s delayed biosimilars in the US. Payers, however, may be more clear sighted.
